Novo Nordisk announced on October 20, 2026, that REDEFINE 1 trial post-study analyses of 2,309 women with obesity or overweight receiving 2.4 mg CagriSema showed 25% average weight loss at 68 weeks versus 3% for placebo under uninterrupted treatment